CN111728987A - Traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection - Google Patents
Traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection Download PDFInfo
- Publication number
- CN111728987A CN111728987A CN202010659096.8A CN202010659096A CN111728987A CN 111728987 A CN111728987 A CN 111728987A CN 202010659096 A CN202010659096 A CN 202010659096A CN 111728987 A CN111728987 A CN 111728987A
- Authority
- CN
- China
- Prior art keywords
- treating cervical
- traditional chinese
- cervical hpv
- penetrating fluid
- shiitake mushroom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Communicable Diseases (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection. The traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection is prepared by mixing a shiitake extract and a penetration enhancer. The invention has high bioavailability, obvious effect proved by efficacy tests, convenient use for patients and worth clinical popularization and application.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection.
[ background of the invention ]
The HPV virus is a specific epitheliophilic virus and can cause genital tract infection, wherein the types 16, 18, 52 and 84 belong to cervical high-risk HPV virus infection, which causes serious damage to the health of patients, and the treatment work faces a larger challenge.
In recent years, the incidence of cervical cancer patients in China is on an increasing trend year by year and the trend of the cervical cancer patients in China is obvious, and Human Papilloma Virus (HPV) is a main risk factor for inducing diseases, so the clinical importance of prevention, control and treatment of the HPV virus is continuously increased. Among them, cervical HPV16, 18, 52, 84 type infections are more frequent in clinic and have high risk, and conventional drug therapy cannot achieve expected effects, so that the use value of traditional Chinese medicine therapy intervention is highlighted.
A new study announced by the American society for gynecological tumors, 45 th annual meeting, found that Lentinus edodes extract can kill sexually transmitted virus HPV (human papilloma virus) causing cervical cancer. At present, health products of mushroom extract which can be orally taken are developed on the market, but the oral medicines have poor bioavailability and the degree of medicine absorption is not ideal. Generally, oral absorption is only 30% or less. To compensate for this effect, large doses are often required to achieve the desired therapeutic amount of drug absorbed. The direct external application of the medicine to the infected part is a better method, however, when the medicine is externally applied, due to the barrier effect of skin (particularly horny layer) on the transdermal absorption of the medicine, except a few small molecular medicines with small dosage and proper solubility, the transdermal speed of most medicines can not meet the treatment requirement, so the technical problem which needs to be solved is how to overcome the skin barrier effect, improve the transdermal speed of the medicine for treating HPV cervix uteri and promote the transdermal penetration of the medicine to achieve the treatment amount within a certain time.
[ summary of the invention ]
The invention aims to: aiming at the defects of the prior art, the traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection is provided, the penetrating fluid can effectively promote the transdermal absorption of the shiitake extract, has high bioavailability, and is proved by a pharmacodynamic test to have remarkable effect, convenient use for patients and worthy of clinical popularization and application.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a Chinese medicinal penetrant for treating cervical HPV infection is prepared from Lentinus Edodes extract and penetration enhancer by mixing.
Further, the penetration enhancer is composed of phenol, menthol and polysorbate 80.
Preferably, the penetration enhancer is prepared by mixing 1-3 parts by weight of phenol, 3-5 parts by weight of menthol and 805-10 parts by weight of polysorbate.
Further, the shiitake extract is a water extract of shiitake mushroom.
Further, the shiitake extract is prepared by the following method: taking shiitake mushroom, adding 10-15 times of water, extracting at 90-100 ℃ for 3-4 hours, filtering, and concentrating the filtrate to half of the original volume to obtain the shiitake mushroom extract.
In the invention, the weight ratio of the shiitake extract to the penetration enhancer is 100 (2-3).
In the invention, the HPV virus infection is HPV18 and 52 type infection.
In summary, due to the adoption of the technical scheme, the invention has the beneficial effects that:
(1) the shiitake extract contains both fat-soluble substances and water-soluble substances, and contains both organic substances with large molecular weight and inorganic substances with small molecular weight, so that the transdermal absorption promoters are selected according to the transdermal properties of different substances.
The inventor of the invention researches and screens various different kinds of penetration enhancers and the influence of the combined application of the penetration enhancers on the in-vitro transdermal absorption of the drug of the invention, screens out the penetration enhancers capable of effectively promoting the in-vitro transdermal absorption of the drug of the invention, and determines the penetration enhancer combination with the best penetration enhancement effect. The present invention has been completed based on this finding.
Among them, phenol can destroy the highly ordered structure of the stratum corneum, increase the fluidity of intercellular lipids of the stratum corneum, and promote the entry of drugs into the stratum corneum. Menthol can interact with lipid in the horny layer to increase intercellular micropores, promote the diffusion of the medicine and generate better permeation-promoting effect on various hydrophilic and lipophilic medicines. Polysorbate 80 is a nonionic surfactant, does not exist in an ionic state in a solution, has high stability, is not easily influenced by the existence of strong electrolyte and acid and alkali, can permeate into the skin and act with keratin in the horny layer to damage the integrity of the horny layer and destroy the barrier action of the skin, and is favorable for the permeation of medicaments.
The phenol, the menthol and the polysorbate 80 are used together, so that the synergistic transdermal promoting effect is obvious, the transdermal absorption of the shiitake extract can be effectively promoted, the bioavailability is high, and the effect test proves that the effect is obvious.
(2) The traditional Chinese medicine penetrating fluid provided by the invention directly contacts the affected part, has a quick response, and can play a significant role in penetrating the pathological mucosa, so that the traditional Chinese medicine penetrating fluid has a strong treatment effect on cervical HPV infected patients, is quick in response, is convenient for patients to use, and is worthy of clinical popularization and application.
[ detailed description ] embodiments
Example 1
A Chinese medicinal penetrating fluid for treating cervical HPV virus infection is prepared by mixing Lentinus Edodes extract and penetration enhancer at a weight ratio of 100: 2.
Wherein the penetration enhancer is prepared by mixing 2 parts by weight of phenol, 4 parts by weight of menthol and 807 parts by weight of polysorbate.
The shiitake extract is prepared by the following steps: taking shiitake mushroom, adding 12 times of water, extracting for 3 hours at 90-100 ℃, filtering, and concentrating the filtrate to half of the original volume to obtain the shiitake mushroom extract.
Example 2
A Chinese medicinal penetrating fluid for treating cervical HPV virus infection is prepared by mixing Lentinus Edodes extract and penetration enhancer at a weight ratio of 100: 2.
Wherein the penetration enhancer is prepared by mixing 1 part by weight of phenol, 5 parts by weight of menthol and 805 parts by weight of polysorbate.
The shiitake extract is prepared by the following steps: taking shiitake mushroom, adding 10 times of water, extracting at 90-100 ℃ for 4 hours, filtering, and concentrating the filtrate to half of the original volume to obtain the shiitake mushroom extract.
Example 3
A Chinese medicinal penetrating fluid for treating cervical HPV virus infection is prepared by mixing Lentinus Edodes extract and penetration enhancer at a weight ratio of 100: 3.
Wherein, the penetration enhancer is prepared by mixing 3 weight parts of phenol, 3 weight parts of menthol and 8010 weight part of polysorbate.
The shiitake extract is prepared by the following steps: taking shiitake mushroom, adding 15 times of water, extracting for 3 hours at 90-100 ℃, filtering, and concentrating the filtrate to half of the original volume to obtain the shiitake mushroom extract.
Example 4
A Chinese medicinal penetrating fluid for treating cervical HPV virus infection is prepared by mixing Lentinus Edodes extract and penetration enhancer at a weight ratio of 100: 3.
Wherein the penetration enhancer is prepared by mixing 1 part by weight of phenol, 5 parts by weight of menthol and 8010 parts by weight of polysorbate.
The shiitake extract is prepared by the following steps: taking shiitake mushroom, adding 10-15 times of water, extracting at 90-100 ℃ for 3-4 hours, filtering, and concentrating the filtrate to half of the original volume to obtain the shiitake mushroom extract.
Comparative example (without penetration enhancer)
A traditional Chinese medicine liquid for treating cervical HPV virus infection is prepared according to the following method: taking shiitake mushroom, adding 12 times of water, extracting for 3 hours at 90-100 ℃, filtering, and concentrating the filtrate to half of the original volume to obtain the shiitake mushroom extract.
In order to explain the effects of the present invention, the applicant conducted the following observation tests.
1 data and method
1.1 general data
72 cases of cervical infection patients collected in 5-2020 in 2018 are selected as study objects, and are divided into a treatment group and a control group by clinicians through an equidistant random sampling method. The treatment group had 36 cases aged 19-42 years, with the mean age (33.76 ± 2.75) years; HPV virus types: 21 cases of 18 types and 15 cases of 52 types. 36 control groups, age 20-45 years, mean age (33.92 + -3.19) years; HPV virus types: 17 cases of type 18 and 19 cases of type 52.
Inclusion criteria were: (1) the patient signs an informed consent; (2) meets the clinical diagnosis standard of cervical HPV infection, and is HPV18 and 52; (3) sexual experience. Exclusion criteria: (1) patients in gestation and lactation periods are excluded; (2) patients who failed to fit were excluded. The general data differences of the age, HPV virus typing and the like of two groups of patients have no statistical significance (P is more than 0.05), and the data are comparable.
1.2 methods
The treatment group was administered the Chinese medicinal permeate of example 1 in combination with interferon (adafen, national drug standard S20020103, Anhui Anke department bioengineering (group) GmbH), wherein the Chinese medicinal permeate was used by the following method: cleaning vagina before sleep, and placing the liquid medicine into fornix vaginae position 1 time/d, 15ml 1 time, 1 time every other day, and continuously taking the medicine for 3 weeks. The interferon is administered by directly placing into fornix vaginae close to cervix, and administering before sleep. 1 granule each time, every other day.
The control group was administered the shiitake extract of the comparative example in combination with interferon therapy, and the method of use was the same as that of the treatment group.
The two groups start to take medicine on the 3 rd day after the end of menstruation, and stop taking medicine during menstruation; sexual life is prohibited during administration, and the dosage is adjusted according to patient recovery condition.
1.3 therapeutic efficacy determination
The effect is shown: after treatment, the focus of the patient is reduced, the color and the property of the patient reach or approach the normal standard, the clinical symptoms disappear, and the disease is basically cured. The method has the following advantages: after treatment, the focus of a patient is obviously reduced, the tissue and the color of the focus are improved, and the clinical symptoms are relieved. And (4) invalidation: after treatment, the range of the focus of a patient has no sign of reduction, and the clinical symptoms are not obviously relieved.
The effective rate of the treatment is obvious effect, effective/obvious effect, effective and ineffective.
1.4 Observation index
(1) HPV viral load before and after treatment was compared. HPV viral load was detected before and after treatment using second generation hybrid capture technology, respectively.
(2) Comparing the negative conversion rate. And taking cervical exfoliated cells to carry out BPV virus infection detection.
1.5 statistical treatment
All data in the study are processed by SPSS17.0 statistical software, and the measurement data are average +/-standard deviation
Expressed as t test, count data utilization (%) and x2The test shows that P < 0.05 indicates that the difference has statistical significance.
2 results
2.1 comparison of the effective treatment rates of two groups of patients
The effective rate of the patients in the control group is 75%, the effective rate of the patients in the treatment group is 86.11%, and the difference has statistical significance (P is less than 0.05). As in table 1.
TABLE 1 comparison of effective treatment rates of two groups of patients [ n (%) ]
2.2 comparison of HPV viral load before and after treatment in two groups of patients
Before treatment, the HPV viral load of two groups of patients is compared, and the difference is not statistically significant (P is more than 0.05); after treatment, patients in the treated group had lower HPV viral loads than the control group, and the differences were statistically significant (P < 0.05) compared among the groups. As shown in table 2.
TABLE 2 comparison of HPV viral load before and after treatment of two groups of patients
2.3 comparison of the negative conversion rates of HPV viruses after treatment in two groups of patients
The negative conversion rate of HPV virus in the control group of patients after treatment is 80.56%, the negative conversion rate in the treatment group is 89.89%, and the difference has statistical significance (P is less than 0.05). As shown in table 3.
TABLE 3 comparison of HPV viral negative conversion rates after treatment of two groups of patients [ n (%) ]
It can be seen that after treatment, the treatment group has better treatment effect by adopting the traditional Chinese medicine penetrating fluid, while the treatment effect of the control group is to be improved.
The above description is intended to describe in detail the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the claims of the present invention, and all equivalent changes and modifications made within the technical spirit of the present invention should fall within the scope of the claims of the present invention.
Claims (7)
1. A traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection is characterized by being prepared by mixing a shiitake mushroom extract and a penetration enhancer.
2. The Chinese medicinal penetrant for treating cervical HPV viral infection according to claim 1, wherein the penetration enhancer is composed of phenol, menthol and polysorbate 80.
3. The Chinese medicinal penetrant for treating cervical HPV viral infection according to claim 1 wherein the penetration enhancer is a mixture of phenol 1-3 parts by weight, menthol 3-5 parts by weight, and polysorbate 805-10 parts by weight.
4. The Chinese medicinal penetrant for treating cervical HPV viral infection according to claim 1, wherein the shiitake mushroom extract is an aqueous extract of shiitake mushroom.
5. The Chinese medicinal permeate for treating cervical HPV viral infection according to claim 1, wherein the shiitake mushroom extract is prepared according to the following method: taking shiitake mushroom, adding 10-15 times of water, extracting at 90-100 ℃ for 3-4 hours, filtering, and concentrating the filtrate to half of the original volume to obtain the shiitake mushroom extract.
6. The traditional Chinese medicine penetrating fluid for treating cervical HPV viral infection according to claim 1, wherein the weight ratio of the shiitake mushroom extract to the penetration enhancer is 100 (2-3).
7. The Chinese medicinal penetrant for treating cervical HPV viral infection according to claim 1, wherein the HPV viral infection is HPV18, 52 type infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010659096.8A CN111728987A (en) | 2020-07-09 | 2020-07-09 | Traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010659096.8A CN111728987A (en) | 2020-07-09 | 2020-07-09 | Traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111728987A true CN111728987A (en) | 2020-10-02 |
Family
ID=72655813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010659096.8A Pending CN111728987A (en) | 2020-07-09 | 2020-07-09 | Traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111728987A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050036112A (en) * | 2003-10-15 | 2005-04-20 | 김진동 | Composition comprising the extract of african ganoderma mushroom having human papilloma virus activity |
| US20070155681A1 (en) * | 2004-12-16 | 2007-07-05 | Leland Shapiro | Methods and compositions for treatment of viral infections |
| CN106474147A (en) * | 2016-10-14 | 2017-03-08 | 上海颉隆投资管理有限公司 | A kind of dressing of prevention and control human papillomaviral infection and preparation method thereof |
| CN108721544A (en) * | 2018-04-25 | 2018-11-02 | 四川生命源健康管理有限公司 | The externally-applied female of anticancer function is sprayed |
-
2020
- 2020-07-09 CN CN202010659096.8A patent/CN111728987A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050036112A (en) * | 2003-10-15 | 2005-04-20 | 김진동 | Composition comprising the extract of african ganoderma mushroom having human papilloma virus activity |
| US20070155681A1 (en) * | 2004-12-16 | 2007-07-05 | Leland Shapiro | Methods and compositions for treatment of viral infections |
| CN106474147A (en) * | 2016-10-14 | 2017-03-08 | 上海颉隆投资管理有限公司 | A kind of dressing of prevention and control human papillomaviral infection and preparation method thereof |
| CN108721544A (en) * | 2018-04-25 | 2018-11-02 | 四川生命源健康管理有限公司 | The externally-applied female of anticancer function is sprayed |
Non-Patent Citations (3)
| Title |
|---|
| 佚名: "香菇萃取物可防官颈癌", 《益寿宝典》 * |
| 佚名: "香菇萃取物可防宫颈癌", 《中华中医药学刊》 * |
| 冯年平，朱全刚主编: "《中药及功效性化妆品经皮给药技术》", 31 May 2019, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016173486A1 (en) | Use of trimethazine in preparation of drugs for preventing and treating liver diseases | |
| CA3166282A1 (en) | Use of pharmaceutical composition for preventing and treating novel coronavirus pneumonia | |
| CN1943600A (en) | Medicinal composition containing American cockroach and its ethanol extract and new use | |
| Whitaker et al. | Intraoral molluscum contagiosum | |
| JP5577129B2 (en) | Liver function improving agent in patients with viral hepatitis | |
| CN1824269A (en) | Xinshenghua oral liquid and its preparation method | |
| CN111588780A (en) | Traditional Chinese medicine composition for treating cervical HPV (human papillomavirus) infection and preparation method thereof | |
| Horowitz et al. | Thalidomide‐induced toxic epidermal necrolysis | |
| TWI538678B (en) | Use of pharmaceutical compositions containing selenite-containing compounds | |
| WO2022199049A1 (en) | Use of ulinastatin in preparation of drug for treating novel coronavirus pneumonia | |
| WO2019128510A1 (en) | Application for pien tze huang and preparation thereof in treatment of herpes zoster | |
| CN111728987A (en) | Traditional Chinese medicine penetrating fluid for treating cervical HPV virus infection | |
| Travis et al. | Successful Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod 5% Cream in a Lung Transplanted Patient. | |
| CN1165343C (en) | Indications for use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses | |
| CN110693988A (en) | Traditional Chinese medicine preparation for treating cervical HPV (human papillomavirus) infection and preparation method thereof | |
| CN1155380C (en) | Application of sophocarpidine oxide in preparing medicine to treat ulcerative colitis | |
| CN113144115A (en) | Traditional Chinese medicine composition for treating verruca vulgaris and application thereof | |
| CN109821007B (en) | Application of bitter gourd protein in preparing medicine for resisting human papilloma virus infection | |
| US20070032558A1 (en) | Method of treating herpes viral infections using a halogenated hydrocarbon composition | |
| Balato et al. | Development of primary varicella infection during infliximab treatment for psoriasis | |
| CN1965893A (en) | Liquid formulation for treating allergic rhinitis | |
| Ni et al. | Meta-analysis of randomized controlled trials of podophyllotoxin nanogel in the treatment of condyloma acuminatum | |
| CN112089841A (en) | Pharmaceutical composition for treating diseases caused by virus infection of epithelial tissues | |
| US20100144855A1 (en) | APPLICATION OF SEDOISOPROSAN FOR PREPARATION OF MEDICINE FOR TREATMENT OF HUMAN HBeAg POSITIVE CHRONIC HEPATITIS B | |
| Cai et al. | Clinical Observation of rhIL-2 Combined with Zhenqi Fuzheng and BaofuKang Suppository in the Treatment of Cervical Intraepithelial Neoplasia II with HPV Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201002 |
|
| RJ01 | Rejection of invention patent application after publication |